C-10299

C-10299 is a deuterated isotopolog of Atazanavir, an antiretroviral drug classified as a protease inhibitor. Developed by Concert Pharmaceuticals, C-10299 is designed to potentially improve the pharmacokinetic or metabolic properties of Atazanavir through the selective incorporation of deuterium. Atazanavir functions by binding to and inhibiting the active site of the HIV-1 protease enzyme, which is essential for the virus to process its polyproteins into functional components. This inhibition prevents the formation of mature, infectious HIV particles, thereby reducing viral replication and serving as a treatment for HIV/AIDS.